๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› HER2- Negative Breast Cancer
Clinical trial register · United States · industry-sponsored

HER2- Negative Breast Cancer Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
Florida 7 Arizona 6 California 6 Colorado 5 Michigan 4
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Relay Therapeutics, Inc.2 Dren Bio1 RayzeBio, Inc.1 Olema Pharmaceuticals, Inc.1 Processa Pharmaceuticals1
State
Florida7 Arizona6 California6 Colorado5 Michigan4
All 27 states
Target enrolment
to
9 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
Relay Therapeutics, Inc.
Phase 3
540
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2025-08-26
Recruiting
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
Dren Bio
Phase 1
96
Colorado, Florida, North Carolina, Oklahoma, South Carolina, Texas, Virginia
2025-06-03
Recruiting
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
BeOne Medicines
Phase 1
120
Iowa, Texas, Washington
2025-02-04
Recruiting
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
Processa Pharmaceuticals
Phase 2
90
Arizona, California, Florida, Indiana, Maryland, New Jersey, New York, Ohio
2024-10-02
Active, closed
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
RayzeBio, Inc.
Phase 1/2
16
Arizona, California, Colorado, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-07-19
Active, closed
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
Nuvation Bio Inc.
Phase 1/2
466
Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington
2024-03-14
Active, closed
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT05607004Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Atossa Therapeutics, Inc.
Phase 2
87
Arizona, California, Florida, Illinois, Kentucky, Michigan, Minnesota, Missouri
2023-02-14
Active, closed
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
NCT05508906Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 1
190
Arizona, California, Colorado, Florida, Iowa, Massachusetts, Michigan, Minnesota
2022-08-31
Recruiting
First-in-Human Study of Mutant-selective PI3Kฮฑ Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
NCT05216432PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer
Relay Therapeutics, Inc.
Phase 1
930
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Massachusetts
2021-12-08
Rows per page Showing 1–9 of 9
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/her2-negative-breast-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.